Lilly Japan Set for Leading Spot in All Core Areas in 2025, “No Plan to Replicate” Redundancy Program: Chief

Lilly Japan President Simone Thomsen Eli Lilly Japan aims to be a leading company in all of its five key strategic areas by 2025, anticipating an “unprecedented number” of new drug approvals and indications coming over the next five years,...read more